Abstract
During pre- and early postnatal development, the neurotransmitter serotonin (5-HT) modulates cell proliferation, migration and programmed cell death, as well as cell shape and cell-cell coupling. These “trophic” effects of 5-HT, involving the cytoskeletal function, the cell cycle, and programmed cell death, can be both dependent and independent of the changes in resting membrane potential that typically define neurotransmitter action. The morphogenetic role of 5-HT is neither limited to the central nervous system (CNS), nor does it impinge upon just a single aspect of cell biology. Ontogenic differences in regional and temporal expression patterns of 5-HT receptors mediating these effects in different systems add further complexity. This review summarizes neurobiological evidence for the trophic involvement of 5-HT during development and discusses related medical issues, including potential teratological risks and possible novel therapeutic indications of selective serotonin reuptake inhibitor (SSRI) administration.
Keywords: 5-hydroxytryptamine, 5-ht receptor, actin, barrel, monoamine oxidase a, serotonin transporter, vesicular monoamine transporter, whisker
Current Neuropharmacology
Title: Roles for Serotonin in Neurodevelopment: More than just Neural Transmission
Volume: 2 Issue: 4
Author(s): G. Di Pino, R. Moessner, K. P. Lesch, J. M. Lauder and A. M. Persico
Affiliation:
Keywords: 5-hydroxytryptamine, 5-ht receptor, actin, barrel, monoamine oxidase a, serotonin transporter, vesicular monoamine transporter, whisker
Abstract: During pre- and early postnatal development, the neurotransmitter serotonin (5-HT) modulates cell proliferation, migration and programmed cell death, as well as cell shape and cell-cell coupling. These “trophic” effects of 5-HT, involving the cytoskeletal function, the cell cycle, and programmed cell death, can be both dependent and independent of the changes in resting membrane potential that typically define neurotransmitter action. The morphogenetic role of 5-HT is neither limited to the central nervous system (CNS), nor does it impinge upon just a single aspect of cell biology. Ontogenic differences in regional and temporal expression patterns of 5-HT receptors mediating these effects in different systems add further complexity. This review summarizes neurobiological evidence for the trophic involvement of 5-HT during development and discusses related medical issues, including potential teratological risks and possible novel therapeutic indications of selective serotonin reuptake inhibitor (SSRI) administration.
Export Options
About this article
Cite this article as:
Pino Di G., Moessner R., Lesch P. K., Lauder M. J. and Persico M. A., Roles for Serotonin in Neurodevelopment: More than just Neural Transmission, Current Neuropharmacology 2004; 2(4) . https://dx.doi.org/10.2174/1570159043359495
DOI https://dx.doi.org/10.2174/1570159043359495 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Prostate Cancer Molecular Background: The IGF-1Ec Story
Clinical Cancer Drugs Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?
Current Cancer Drug Targets Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets Beneficial Action of Citrus Flavonoids on Multiple Cancer-Related Biological Pathways
Current Cancer Drug Targets Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes
Current Pharmaceutical Design Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Profiling the Shear Stress of Atherosclerosis; A Genomic View
Current Genomics Virotherapy as An Approach Against Cancer Stem Cells
Current Gene Therapy Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Current Drug Targets A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Current Pharmaceutical Design mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Cisplatin Is a DNA-Damaging Antitumour Compound Triggering Multifactorial Biochemical Responses in Cancer Cells: Importance of Apoptotic Pathways
Current Medicinal Chemistry - Anti-Cancer Agents The Neurotrophic and Antiangiogenic Functions of PEDF: A Reflection of its Variable Phosphorylation States
Current Genomics Modulation of Sirtuins: New Targets for Antiageing
Recent Patents on CNS Drug Discovery (Discontinued) From Dual Peroxisome Proliferator Activated Receptor Agonists to Selective Peroxisome Proliferator Activated Receptor Modulators
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery TGF-ß / Smad Signaling in Prostate Cancer
Current Drug Targets Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design